Live Feeds
● TRACKER Updated 7d ago · 7 sources tracked

Novo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped

Novo Nordisk has canceled two phase 3 cardiovascular trials for ziltivekimab, a drug designed to reduce inflammation and treat heart failure. These cancellations limit the company's ability to expand its growth beyond obesity treatments. Conversely, Novo Nordisk reports that semaglutide, marketed as Wegovy, successfully reduced obesity rates and helped children lose weight in recent clinical trials. The company now faces a split trajectory between failing heart disease programs and expanding pediatric applications for its weight loss portfolio.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (7)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Novo Nordisk stopped two cardiovascular trials for a drug aimed at lowering inflammation.
  • ✓ The company halted two heart failure studies for ziltivekimab.
  • ✓ Semaglutide helped children lose weight and reduced obesity rates in a trial.
🛡️ Source Corroboration: 7 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Novo Nordisk stopped two cardiovascular trials for ziltivekimab and reported positive weight loss results for Wegovy in children.

Live updates

  1. Novo Nordisk Halts Cardiovascular Trials While Wegovy Shows Success in Children

    Novo Nordisk has canceled two phase 3 cardiovascular trials for ziltivekimab, a drug designed to reduce inflammation and treat heart failure. These cancellations limit the company's ability to expand its growth beyond obesity treatments. Conversely, Novo Nordisk reports that semaglutide, marketed as Wegovy, successfully reduced obesity rates and helped children lose weight in recent clinical trials. The company now faces a split trajectory between failing heart disease programs and expanding pediatric applications for its weight loss portfolio.

    Why it matters

    The company has sought to diversify its revenue streams to avoid over-reliance on GLP-1 agonists. Heart failure and chronic kidney disease programs represented a strategic effort to enter the broader cardiovascular market. Success in pediatric obesity trials expands the addressable market for Wegovy.

    What is confirmed

    • Novo Nordisk stopped two cardiovascular trials for a drug aimed at lowering inflammation.
    • The company halted two heart failure studies for ziltivekimab.
    • Semaglutide helped children lose weight and reduced obesity rates in a trial.

    What to watch next

    • Regulatory filing dates for pediatric Wegovy use
    • Updated guidance on the chronic kidney disease program pipeline
    Sources used for this update (7)
    1. WSJ — Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial
    2. reuters.com — Novo Nordisk says semaglutide cut obesity rates in young children in trial
    3. Fierce Biotech — Novo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped
    4. Reuters — Novo scraps two more heart drug trials, further dimming growth beyond obesity
    5. STAT — Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation
    6. FirstWord Pharma — Novo's hopes for ziltivekimab dwindle as two heart failure studies stopped early
    7. Bloomberg.com — Novo Nordisk Ends Heart Disease Drug Trials in Fresh Setback
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community